Biome Grow subsidiary, Highland Grow secures purchase order with NSLC and sends first shipment of finished product
ANTIGONISH, Nova Scotia, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Biome Grow Inc. (“Biome” or the “Company”) (CSE: BIO) (Frankfurt: 6OTA) (OTCQB: BIOIF) is pleased to announce its Nova Scotia-based subsidiary, Highland Grow Inc. (“Highland Grow”), has secured its first purchase order with the Nova Scotia Liquor Corporation (“NSLC”). The first shipment of finished product grown and packaged specifically for consumers in Nova Scotia is expected to be received by the NSLC later today.
This is the first shipment of what the Company expects to be regular deliveries to the NSLC. The first shipment consists of three genetic varieties well suited to the tastes of the local market. Highland Grow anticipates expanding its genetic and product offerings with subsequent shipments starting later this month. Through this first allotment of products, the Company will be looking to validate its localized approach to its domestic market, which in this case will also be supported by special positioning of its products in NSLC retail locations.
Today’s announcement is the culmination of our professional expertise and experience in the cannabis market and the Company’s localized approach to building provincial brands which serve the unique requirements of its local cannabis consumers.
“As a team of proud Nova Scotians, we are excited to see the first shipment being delivered from our locally established facility to the Nova Scotia consumer,” said Frank MacMaster, President of Highland Grow. “Biome and Highland Grow are preparing to meet the unprecedented increase in demand and do our part to eliminate the current supply shortage in our home Province, and throughout Canada’s legalized cannabis market.”
About Highland Grow Inc.
Highland Grow is the first of Biome Grow’s facilities licensed for production and sales. Highland Grow’s production facility is located in Antigonish, Nova Scotia, it has a total footprint of 6,500 square feet and resides on 19 acres of farmland. Additionally, Biome Grow continues to grow in Atlantic Canada with more facilities under development, bringing the total footprint to 174,500 square feet in this region.
For further information, please contact:
Biome wholly owns five subsidiaries, including: The Back Home Medical Cannabis Corporation, a company incorporated under the laws of the Province of Newfoundland and Labrador and in the late stages of applying for a license under the Cannabis Act; Great Lakes Cannabis, a company incorporated under the laws of the Province of Ontario and in the late stages of applying for a license under the ACMPR; Highland Grow Inc., a licensed producer in Nova Scotia under Canada’s Cannabis Act; Red Sands Craft Cannabis Co., a company incorporated under the laws of the Province of Prince Edward Island, and; Weed Virtual Retail Inc., a company incorporated under the laws of the Province of Ontario in the business of operating a new virtual reality technology platform focused exclusively on the medical and recreational cannabis markets. Biome is a Canadian-based company with national and international business interests.
This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, “ expects” or “does not expect”, “proposed”, “is expected”, “budgets”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward‐looking statements and information concerning: the expected timing associated with the first shipment of product, the timing associated with subsequent shipments of product, future genetic and product offerings and the overall demand in the Province and Canada. Such forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to Biome, including, among other things, assumptions and expectations with respect to: the Cannabis Act and its regulations continuing to exist and operate as expected; the continued existence and validity of the license granted to Highland Grow; changes in cannabis research or the general public’s perception of cannabis; and the ability to operate the business as expected.
These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements speak only as of the date on which they are made, and Biome, or any of its subsidiaries undertakes no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
ISSI HyperFlash™ memory has successfully been designed into the NXP i.MX RT106A MCU-based solution for AVS (Alexa Voice Service)19.3.2019 21:30:00 CET | Pressemelding
MILPITAS, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Integrated Silicon Solution, Inc. a leader in advanced memory solutions, today announced the adoption of HyperFlash™ memory IS26KL256S-DABLI00 (256Mb 3.3V BGA package) with NXP’s i.MX RT106A MCU based solution for AVS (Alexa Voice Service). The Alexa Voice Service (AVS) is a virtual assistant developed by Amazon that provides cloud-based automatic speech recognition (ASR) and natural language understanding (NLU) to provide information, media playback, communication and smart device control capabilities to consumers. HyperFlash™ memory based on the HyperBus™ technology dramatically improves memory performance while reducing pin count and board space, essential for NXP’s implementation to save BOM cost without compromising performance to do XIP (execute-in-place) operations. “NXP is an important partner for us. We are very glad that NXP adopted our HyperFlash™ solution. HyperFlash™ fits nicely in the application to meet the increasingl
NLS Pharmaceutics Announces the Completion of the Merger between NLS Pharma Ltd., NLS-1 Pharma Ltd. and NLS-0 Pharma, Unifying the Global Operations and Development of Nolazol®19.3.2019 21:05:00 CET | Pressemelding
The combined company was named NLS Pharmaceutics Ltd (NLS) STANS, Switzerland, March 19, 2019 (GLOBE NEWSWIRE) -- NLS Pharmaceutics Ltd (NLS), a Swiss biotech firm focusing on the development of novel treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) and other cognitive disorders and impairments, today announced the closing of the merger of NLS Pharma Ltd., NLS-1 Pharma Ltd. and NLS-0 Pharma, effective immediately. The combined company was named “NLS Pharmaceutics Ltd.” The sideways merger brings together the global operations and assets of the three companies in order to streamline the development of Nolazol®, a controlled release formulation of mazindol that is currently being developed as a non-amphetamine DEA schedule C-4 treatment option for ADHD and narcolepsy, as well as a promising pipeline of early to late-stage compounds focusing on ADHD, sleep disorder and other rare diseases. Leading the combined company as Chief Executive Officer is Alex Zwyer, who served as c
INVNT Recognised for Xero and TEDxSydney Work at The Event Marketing Awards 201919.3.2019 14:30:00 CET | Pressemelding
HONG KONG, March 19, 2019 (GLOBE NEWSWIRE) -- INVNT, the global live brand storytelling agency™, in partnership with Xero has received the Best Corporate Event Gold Award at the prestigious Event Marketing Awards 2019 organised by Campaign Asia-Pacific and CEI, for its production, management and design of Xerocon Brisbane 2018 – Australasia’s largest technology conference for the accounting industry. During the ceremony, which was held at the Eaton Club in Hong Kong on Tuesday evening local time, INVNT was also recognised with the Best Sustainability Bronze Award alongside client TEDxSydney, for the production of the not-for-profit organisation’s flagship event in 2018, which was themed around the concept of HumanKind and saw the agency devise and implement a series of environmentally friendly initiatives. Now in their fourth year, the Event Marketing Awards organised by Campaign Asia-Pacific and CEI recognise best practice in the creation, planning, production and management of innova
Crocus Technology Unveils its 2nd Generation TMR Linear Sensor with Unparalleled Temperature Stability19.3.2019 13:00:00 CET | Pressemelding
The CT100 is a unique TMR magnetic sensor with industry-leading performance SANTA CLARA, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Crocus Technology Inc., a leading supplier of disruptive Tunnel Magneto-Resistance (TMR) sensors, today announces the CT100 device, an advanced, high-performance linear (1D) magnetic sensor based on Crocus’ patented and unique TMR-based technology. The CT100 has best-in-class performance across a wide temperature range coupled with an extremely low linearity error, low hysteresis, and low noise which enables it to address many consumer, industrial and automotive applications and markets. The CT100 outperforms competitors’ xMR or Hall-based linear magnetic sensor technology available today in terms of performance, deviation over temperature, current consumption, and overall robustness. The CT100 does not require any expensive flux guides or concentrators, chopping circuits or set/reset pulses and operates over a wide magnetic field range. Crocus’s revolutio
Despite Brexit Uncertainty, Business Schools in UK Continue to See Strong International Demand19.3.2019 09:00:00 CET | Pressemelding
Majority of Candidates Say Brexit has No Impact on Decision to Study in the United Kingdom RESTON, Va., March 19, 2019 (GLOBE NEWSWIRE) -- In response to the initial Brexit vote in June 2016, the Graduate Management Admission Council™ (GMAC™) has been tracking Graduate Management Admission Test™ (GMAT™) examinee interest in studying in the UK. This has included periodic surveys of non-U.K. citizens who sent a GMAT score report to a UK business school program, as an indication of where they are interested in studying. In the immediate aftermath of the vote, it was unclear what the impact would be on the international flow of students to UK programs, which are heavily reliant on enrollees from other countries. Brexit, it’s been feared, could restrict or complicate the student visa process and dampen international candidates’ postgraduation job prospects in the UK, both because of possible changes to work visa policies and jobs leaving the UK. However, the most recent survey findings, fro
General Electric Company: Doc re. GE files DEFA14A19.3.2019 08:00:00 CET | Pressemelding
FAIRFIELD, Conn., March 19, 2019 (GLOBE NEWSWIRE) -- Company ISIN Symbol Headline General Electric Company US3696041033 London: GEC | Paris: GNE Doc re: GE files DEFA14A March 18, 2019 On March 18, 2019, General Electric Company (the "Company") filed a DEFA14A (Definitive Additional Materials) with the U.S. Securities and Exchange Commission ("SEC"), which has been submitted to the U.K. National Storage Mechanism and will be available shortly for inspection at http://www.morningstar.co.uk/uk/NSM. It is also available on the SEC's website at http://www.sec.gov and on the Company's website at https://www.ge.com/investor-relations/events-reports. CONTACT: GE Jennifer Erickson +001 646 682 5620 email@example.com This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this informatio